Title |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
|
---|---|
Published in |
Journal of Hematology & Oncology, January 2017
|
DOI | 10.1186/s13045-016-0380-0 |
Pubmed ID | |
Authors |
Kurt Schönfeld, Chantal Zuber, Jan Pinkas, Thomas Häder, Katrin Bernöster, Christoph Uherek |
Abstract |
Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 26 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 31% |
Researcher | 7 | 27% |
Student > Master | 4 | 15% |
Student > Bachelor | 2 | 8% |
Professor | 1 | 4% |
Other | 2 | 8% |
Unknown | 2 | 8% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 27% |
Biochemistry, Genetics and Molecular Biology | 4 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 12% |
Agricultural and Biological Sciences | 3 | 12% |
Immunology and Microbiology | 2 | 8% |
Other | 4 | 15% |
Unknown | 3 | 12% |